|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
|
ATE272055T1
(de)
*
|
1995-05-01 |
2004-08-15 |
Scarista Ltd |
Nicotinsäureester und diese enthaltende pharmazeutischen zusammensetzungen
|
|
USRE40546E1
(en)
*
|
1996-05-01 |
2008-10-21 |
Scarista, Ltd. |
1,3-Propane diol esters and ethers and methods for their use in drug delivery
|
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
AU3641597A
(en)
|
1996-06-21 |
1998-01-07 |
Advanced Research And Technology Institute, Inc. |
Methods and compositions comprising r-ibuprofen
|
|
AU5105598A
(en)
*
|
1996-11-12 |
1998-06-03 |
American Home Products Corporation |
Indene inhibitors of cox-2
|
|
US5869524A
(en)
*
|
1996-11-12 |
1999-02-09 |
American Home Products Corporation |
Indene inhibitors of COX-2
|
|
AU5727798A
(en)
*
|
1996-12-23 |
1998-07-17 |
Texas A & M University, The |
Anti-amyloidogenic agents
|
|
WO1998046588A2
(en)
|
1997-04-11 |
1998-10-22 |
Neorx Corporation |
Compounds and therapies for the prevention of vascular and non-vascular pathologies
|
|
CA2320202C
(en)
*
|
1998-02-13 |
2010-09-14 |
Nutramax Laboratories, Inc. |
Agents and methods for protection, treatment and repair of connective tissue
|
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
|
US20040073258A1
(en)
*
|
1999-01-06 |
2004-04-15 |
Church W. Edward |
Body tissue and skin treatment method using pulsing heating pad and topical cream
|
|
US6572871B1
(en)
*
|
1999-01-06 |
2003-06-03 |
W. Edward Church |
Pain treatment method and apparatus using heating wrap and analgesic cream
|
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
|
US20060004086A1
(en)
*
|
2000-04-13 |
2006-01-05 |
Mayo Foundation For Medical Education And Research |
Method of reducing Abeta42 and treating diseases
|
|
WO2001078721A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Aβ42 LOWERING AGENTS
|
|
US6306842B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
|
AU2001275036A1
(en)
*
|
2000-06-02 |
2001-12-17 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
|
JP2004505041A
(ja)
|
2000-08-02 |
2004-02-19 |
ファーマニュートリエンツ |
シンドロームxの予防及び治療のための方法及び組成物
|
|
AU2000265107A1
(en)
*
|
2000-08-02 |
2002-02-13 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
|
|
US6927239B1
(en)
|
2000-08-02 |
2005-08-09 |
Pharmanutrients |
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
|
|
US6838451B1
(en)
|
2000-08-02 |
2005-01-04 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
|
|
JP2004538262A
(ja)
*
|
2000-12-14 |
2004-12-24 |
タフツ ユニバーシティー |
関節炎状態を治療するための化合物および方法
|
|
AU2002303164A1
(en)
*
|
2001-03-23 |
2002-10-08 |
Protarga, Inc. |
Fatty amine drug conjugates
|
|
EP1423107B1
(de)
*
|
2001-03-23 |
2012-05-09 |
Luitpold Pharmaceuticals, Inc. |
Fettalkohol-arzneimittel-konjugate
|
|
GB0111282D0
(en)
*
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
|
JP3977162B2
(ja)
*
|
2002-06-21 |
2007-09-19 |
株式会社バンダイナムコゲームス |
キャラクタ情報管理装置、プログラム及び情報記憶媒体
|
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
|
EP1651195A4
(de)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
Pharmazeutische verfahren, dosierschemata und dosierformen zur behandlung von alzheimerkrankheit
|
|
US20050154059A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Cook Mark E. |
Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
|
|
US20090155903A1
(en)
*
|
2004-03-19 |
2009-06-18 |
Myriad Genetics, Incorporated |
Pharmaceutical composition and method
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
EP1745180A1
(de)
*
|
2004-04-29 |
2007-01-24 |
Keystone Retaining Wall Systems, Inc. |
Frontverkleidung für stützwände
|
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
|
EA010802B1
(ru)
*
|
2004-11-19 |
2008-12-30 |
Мартек Байосайенсиз Корпорейшн |
Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
|
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
|
JP2009502807A
(ja)
*
|
2005-07-22 |
2009-01-29 |
ミリアド ジェネティクス, インコーポレイテッド |
薬剤含有率の高い製剤および投与量形態
|
|
EP1983977A4
(de)
*
|
2006-01-31 |
2011-11-30 |
Martek Biosciences Corp |
Oxylipine aus stearidonsäure und gamma-linolensäure sowie verfahren zu ihrer herstellung und verwendung
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
US20110190389A1
(en)
*
|
2007-02-20 |
2011-08-04 |
Linda Arterburn |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
WO2008153722A1
(en)
*
|
2007-05-22 |
2008-12-18 |
The Board Of Regents Of The University Of Texas System |
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
|
|
US20110027841A1
(en)
*
|
2007-12-21 |
2011-02-03 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
|
DK2315740T3
(en)
*
|
2008-07-08 |
2018-01-08 |
Catabasis Pharmaceuticals Inc |
Fatty Acid Acetylated Salicylates and Their Uses
|
|
US9085527B2
(en)
*
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
|
PT2334295T
(pt)
|
2008-09-02 |
2017-09-15 |
Amarin Pharmaceuticals Ie Ltd |
Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
|
|
US20110229565A1
(en)
*
|
2008-09-17 |
2011-09-22 |
Karp Jeffrey M |
Drug Delivery Composition Comprising a Self-Assembled Gelator
|
|
KR20110079693A
(ko)
|
2008-10-29 |
2011-07-07 |
와이어쓰 엘엘씨 |
단일 도메인 항원 결합 분자의 정제 방법
|
|
EP2362767B1
(de)
|
2008-10-29 |
2017-12-06 |
Ablynx N.V. |
Formulierungen von einzeldomänen-antigen-bindungsmolekülen
|
|
US8293727B2
(en)
|
2009-02-10 |
2012-10-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
CN107233337A
(zh)
|
2009-04-29 |
2017-10-10 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
|
SI2424356T1
(en)
|
2009-04-29 |
2018-01-31 |
Armarin Pharmaceuticals Ireland Limited |
A stable pharmaceutical composition and procedures for its use
|
|
WO2010147994A1
(en)
|
2009-06-15 |
2010-12-23 |
Amarin Pharma, Inc. |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
USRE46608E1
(en)
|
2009-09-01 |
2017-11-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
|
US8304551B2
(en)
|
2009-09-01 |
2012-11-06 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
|
US20110064813A1
(en)
*
|
2009-09-16 |
2011-03-17 |
Charles Vaughn |
Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
|
|
MX2012003555A
(es)
|
2009-09-23 |
2012-07-03 |
Amarin Corp Plc |
Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
|
|
CA2785846C
(en)
|
2009-12-31 |
2015-07-07 |
Kempharm, Inc. |
Amino acid conjugates of quetiapine, process for making and using the same
|
|
CN102822141A
(zh)
*
|
2010-01-20 |
2012-12-12 |
普罗诺瓦生物医药挪威公司 |
水杨酸脂肪酸衍生物
|
|
EP2542060B1
(de)
*
|
2010-03-04 |
2019-10-02 |
Amarin Pharmaceuticals Ireland Limited |
Zusammensetzungen zur behandlung und/oder prävention von herz-kreislauf-erkrankungen
|
|
WO2011109681A1
(en)
*
|
2010-03-05 |
2011-09-09 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cox inhibitor derivatives and their uses
|
|
SI2544536T1
(sl)
|
2010-03-11 |
2019-03-29 |
Kempharm, Inc. |
Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
|
|
US20130045939A1
(en)
*
|
2010-03-19 |
2013-02-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid macrolide derivatives and their uses
|
|
AU2011277983C1
(en)
*
|
2010-07-16 |
2016-09-29 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
|
EP2618821A4
(de)
|
2010-09-24 |
2014-08-13 |
Brigham & Womens Hospital |
Nanostrukturierte gele zur kontrollierten freisetzung verkapselter mittel
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
NZ727980A
(en)
|
2010-11-29 |
2018-08-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
WO2012087745A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Nestec S.A. |
Methods and compositions for preventing and treating osteoarthritis
|
|
EP2760433B1
(de)
|
2011-09-29 |
2023-05-31 |
PLx Opco Inc. |
Ph-abhängige träger zur gezielten freisetzung von pharmazeutika entlang den gastrointestinaltrakts, zusammensetzungen daraus sowie ihre herstellung und verwendung
|
|
EP2775837A4
(de)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
Verfahren zur behandlung von hypertriglyceridämie
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
ES2891473T3
(es)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
|
|
EP3815684B1
(de)
|
2012-06-29 |
2024-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
EP3086793B1
(de)
|
2013-12-24 |
2022-05-11 |
Virginia Commonwealth University |
Verwendung von oxygenierten cholesterinsulfaten (ocs) zur behandlung von nierenstörungen
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
US9603869B2
(en)
|
2015-05-22 |
2017-03-28 |
University Of South Florida |
Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
|
|
AU2016335846B2
(en)
|
2015-10-08 |
2019-04-04 |
The Brigham And Women's Hospital, Inc. |
Stabilized assembled nanostructures for delivery of encapsulated agents
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
EP3452094B1
(de)
|
2016-05-06 |
2021-11-17 |
The Brigham and Women's Hospital, Inc. |
Binäre selbstangeordnete gele zur kontrollierten abgabe von verkapselten wirkstoffen an knorpel
|
|
US11020410B2
(en)
|
2017-02-03 |
2021-06-01 |
The Brigham And Women's Hospital, Inc. |
Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
|
|
JP7211974B2
(ja)
|
2017-05-08 |
2023-01-24 |
アリヴィオ セラピューティクス, インコーポレイテッド |
増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
ES2983568T3
(es)
|
2018-09-24 |
2024-10-23 |
Amarin Pharmaceuticals Ie Ltd |
Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
|
|
EP4058141A4
(de)
|
2019-11-12 |
2023-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Verfahren zum verringern des risikos von kardiovaskulären ereignissen bei einem probanden mit vorhofflimmern und/oder vorhofflattern
|
|
CA3172595A1
(en)
|
2020-03-26 |
2021-09-30 |
Ronald Zimmerman |
Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same
|
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|